Pilot Study of Induction Therapy Followed by Response-adaptive Treatment and Dynamic Changes in Circulating Tumor DNA in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma
University of Chicago
Summary
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must have pathologically confirmed locally advanced, non-metastatic, human papillomavirus (HPV) negative head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses. * Stage III or IV disease based on American Joint Committee on Cancer (AJCC) staging 8th edition. * If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry. * Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior t…
Interventions
- DrugPaclitaxel
Given as part of induction chemotherapy.
- DrugCarboplatin
Given as part of induction chemotherapy.
- DrugCetuximab
Given as part of induction chemotherapy.
- RadiationStandard Dose Radiation
Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
- RadiationLow Dose Radiation
Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
- DrugCisplatin
Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
- Drug
Location
- University of Chicago Medicine Comprehensive Cancer CenterChicago, Illinois